ELUXA 4: a phase I/II study of olmutinib in Japanese patients with EGFR T790M mutation-positive NSCLC
Latest Information Update: 17 Jun 2016
At a glance
- Drugs Olmutinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ELUXA 4
- 17 Jun 2016 New trial record
- 02 Jun 2016 According to Boehringer Ingelheim media release, this trial will be initiated in 2016.